JP7684803B2 - 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 - Google Patents

補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 Download PDF

Info

Publication number
JP7684803B2
JP7684803B2 JP2020500686A JP2020500686A JP7684803B2 JP 7684803 B2 JP7684803 B2 JP 7684803B2 JP 2020500686 A JP2020500686 A JP 2020500686A JP 2020500686 A JP2020500686 A JP 2020500686A JP 7684803 B2 JP7684803 B2 JP 7684803B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
modified polypeptide
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532285A5 (enExample
JP2020532285A (ja
Inventor
パッファー，ブリジット
チャンドラー，ジュリアン
ジェラ，ニミッシュ
エル． シェリダン，ダグラス
ジンダル，シドハース
ピー． タンブリーニ，ポール
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020532285A publication Critical patent/JP2020532285A/ja
Publication of JP2020532285A5 publication Critical patent/JP2020532285A5/ja
Priority to JP2023085796A priority Critical patent/JP2023120208A/ja
Priority to JP2025044077A priority patent/JP2025118590A/ja
Application granted granted Critical
Publication of JP7684803B2 publication Critical patent/JP7684803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020500686A 2017-07-11 2018-07-11 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 Active JP7684803B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023085796A JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2025044077A JP2025118590A (ja) 2017-07-11 2025-03-18 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023085796A Division JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Publications (3)

Publication Number Publication Date
JP2020532285A JP2020532285A (ja) 2020-11-12
JP2020532285A5 JP2020532285A5 (enExample) 2021-11-25
JP7684803B2 true JP7684803B2 (ja) 2025-05-28

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020500686A Active JP7684803B2 (ja) 2017-07-11 2018-07-11 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2023085796A Pending JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2025044077A Pending JP2025118590A (ja) 2017-07-11 2025-03-18 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023085796A Pending JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2025044077A Pending JP2025118590A (ja) 2017-07-11 2025-03-18 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Country Status (12)

Country Link
US (3) US11498960B2 (enExample)
EP (1) EP3625265A1 (enExample)
JP (3) JP7684803B2 (enExample)
KR (3) KR20250068795A (enExample)
CN (3) CN117327188A (enExample)
AU (3) AU2018301412B2 (enExample)
BR (1) BR112019028269A2 (enExample)
CA (1) CA3067247A1 (enExample)
CO (1) CO2020000369A2 (enExample)
IL (3) IL271920B2 (enExample)
MX (2) MX2024005945A (enExample)
WO (1) WO2019014360A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
WO2020092546A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
CA3137018A1 (en) * 2019-04-16 2020-10-22 University Of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
MX2022006514A (es) 2019-12-26 2022-07-11 Eisai R&D Man Co Ltd Composicion farmaceutica que contiene un acido ribonucleico de doble hebra que inhibe la expresion de c5 de complemento.
WO2021144962A1 (ja) 2020-01-17 2021-07-22 オリンパス株式会社 発光装置、および駆動装置
US20230416344A1 (en) 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses
EP4225372A4 (en) * 2020-10-05 2024-11-06 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
WO2024049951A1 (en) * 2022-08-31 2024-03-07 Alexion Pharmaceuticals, Inc. Dosage and administration of fusion polypeptides for treatment of sickle cell disease
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508652A (ja) 2012-02-20 2015-03-23 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合するポリペプチド
JP2016020345A (ja) 2008-08-05 2016-02-04 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) * 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
JP4860702B2 (ja) * 2005-10-21 2012-01-25 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチドのリコンビナント発現のための方法
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
WO2011112850A2 (en) 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
ES2538114T3 (es) 2008-03-03 2015-06-17 Novelmed Therapeutics, Inc. Anticuerpos anti-properdina
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011095545A1 (en) * 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN110437321A (zh) 2010-07-09 2019-11-12 阿菲博迪公司 多肽
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
WO2013006449A2 (en) 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2862448A1 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
AU2013326932B2 (en) 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
KR102497083B1 (ko) 2013-08-28 2023-02-07 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
PT3038633T (pt) 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
KR20230173731A (ko) * 2017-01-30 2023-12-27 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016020345A (ja) 2008-08-05 2016-02-04 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
JP2015508652A (ja) 2012-02-20 2015-03-23 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合するポリペプチド

Also Published As

Publication number Publication date
AU2018301412A9 (en) 2025-08-07
AU2025200303A1 (en) 2025-02-13
CN117327187A (zh) 2024-01-02
US11498960B2 (en) 2022-11-15
CN117327188A (zh) 2024-01-02
MX2024005946A (es) 2024-06-11
CN111201246B (zh) 2023-10-27
JP2023120208A (ja) 2023-08-29
CO2020000369A2 (es) 2020-01-31
US20230235033A1 (en) 2023-07-27
US20200399351A1 (en) 2020-12-24
US20250163138A1 (en) 2025-05-22
RU2020102910A (ru) 2021-08-11
EP3625265A1 (en) 2020-03-25
AU2018301412A1 (en) 2020-01-30
IL271920B2 (en) 2024-03-01
AU2025200313A1 (en) 2025-02-13
US12221473B2 (en) 2025-02-11
AU2018301412B2 (en) 2025-08-07
KR20200026264A (ko) 2020-03-10
CN111201246A (zh) 2020-05-26
IL271920A (en) 2020-02-27
JP2025118590A (ja) 2025-08-13
IL307197A (en) 2023-11-01
KR20250068795A (ko) 2025-05-16
KR102806328B1 (ko) 2025-05-14
IL271920B1 (en) 2023-11-01
WO2019014360A8 (en) 2019-02-21
MX2024005945A (es) 2024-06-11
RU2020102910A3 (enExample) 2021-12-02
BR112019028269A2 (pt) 2020-07-14
IL324119A (en) 2025-12-01
JP2020532285A (ja) 2020-11-12
WO2019014360A1 (en) 2019-01-17
KR20250099285A (ko) 2025-07-01
CA3067247A1 (en) 2019-01-17
IL307197B1 (en) 2025-11-01

Similar Documents

Publication Publication Date Title
JP7684803B2 (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
TW200914465A (en) Humanized antibodies to Aβ(20-42) globulomer and uses thereof
CN103906532B (zh) 结合磷酰胆碱（pc）和/或pc结合物的抗体
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
KR20240038716A (ko) 신규 항-masp-2 항체
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
WO2024108529A1 (en) Properdin binding protein and use thereof
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
US12162931B2 (en) Properdin binding protein and use thereof
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2025208782A1 (en) Cfd-binding antibody fragments and uses thereof
WO2025101747A1 (en) Methods and compositions for treatment of pulmonary hypertension
WO2023034842A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250516

R150 Certificate of patent or registration of utility model

Ref document number: 7684803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150